OBJECTIVES In 2003 Health Transformation Program and in 2006 Social Security Reform were launched in Turkey. At the end of the years 2009 and 2011 price cuts were done by the Government and between the years 2010-2012, there was a global budget implementation in Turkey. Health implications of these developments in the medicine market have not been analyzed in a comprehensive manner. The top 100 medicines, annual average highest amount of sales of between 2008-2013, had one to four of the total pharmaceutical market value in 2013. In this study we aimed to determine these first 100 medicine’s, which have higher total sales amount, defining characteristics. METHODS While pharmaceutical sales data were obtained from the IMS Health-Turkey data base, characteristics of medicines were obtained from the Turkish Medicine And Medical Devices Agency and the Social Security Agency data bases. RESULTS While 78 medicines are original, 22 medicines are generic. 60 medicines are imported medicines, 40 medicines are manufactured medicines. 19 medicines are biotechnological medicines and all of these biotechnological medicines are original and imported. 96 medicines covered by Social Security payments. Equivalent of 65 medicines are available (each equivalent group from 1-30, an average of 13 generics available). 19 medicines and 15 medicines are respectively systemic anti-infectives and antineoplastics and immunomodulating agents. In this study, the license holders of the medicines are 40 firms in total. 15 firms have a market share of 75% and the medicines which, have 77,7% portion of total amount, are created by multinational firms. CONCLUSIONS In the years which were the effects of reforms, price cuts and global budget implementation seen, the medicines which have higher total sales amount were mostly original, imported, covered by Social Security payments and created by multinational firms.